Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
regorafenib + TAS-102 + influenza vaccine
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Vaccines & Immunotherapeutics, Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
The entry **regorafenib + TAS-102-Novartis Vaccines-influenza** appears to be an erroneous concatenation of two distinct therapeutic regimens: an oncology combination and a seasonal influenza vaccine. The oncology component consists of **regorafenib**, a multi-kinase inhibitor targeting angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-beta, FGFR1), and oncogenic (KIT, RET, RAF-1) receptor tyrosine kinases, and **TAS-102** (trifluridine/tipiracil), a combination of a nucleoside metabolic inhibitor and a thymidine phosphorylase inhibitor. These agents are typically investigated together for refractory metastatic colorectal cancer. The vaccine component refers to the seasonal influenza vaccines (adjuvanted with MF59 or unadjuvanted) developed by **Novartis Vaccines**, which were evaluated in pediatric populations in studies such as the V70P5 extension trial. There is no known clinical product or trial that combines these three distinct agents into a single therapeutic intervention.
- Other names
- regorafenib + trifluridine + tipiracil + influenza vaccine
02
Targets
HA (Hemagglutinin)RAF1 (c-Raf-1 (Y340D/Y341D))RET (Rearranged during transfection receptor tyrosine kinase)TEK (Tie2)TYMP (Thymidine phosphorylase)TS (Thymidylate synthase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on regorafenib + TAS-102 + influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on regorafenib + TAS-102 + influenza vaccine.